Navigation Links
ADVENTRX Pharmaceuticals Reports Second Quarter Financial Results
Date:8/12/2009

l clinical trial expenses related to ANX-510, a $0.1 million decrease in external clinical trial expenses related to ANX-514, a $1.2 million decrease in non-clinical expenses related to ANX-514, a $0.6 million decrease in personnel expenses and a $0.1 million decrease in share-based compensation expense.

Selling, general and administrative (SG&A) expenses in the second quarter of 2009 were $1.1 million, a decrease of $1.6 million, or 59%, compared with SG&A expenses of $2.6 million in the second quarter of 2008. The decrease was primarily due to a $1.1 million decrease in personnel costs, a $0.1 million decrease in share-based compensation expense, a $0.2 million decrease in legal and professional services, a $0.1 million decrease in market research expenses and a $0.1 million decrease in travel expenses.

Year-to-Date Financial Results

For the six months ended June 30, 2009, ADVENTRX's net loss applicable to common stock was $7.0 million, or $0.08 per share, compared with a net loss applicable to common stock of $12.4 million, or $0.14 per share, for the comparable period in 2008. Included in the net loss for the 2009 period was a non-cash deemed dividend expense of $1.2 million incurred in connection with the Company's June 2009 equity financing. Net loss for the six months ended June 30, 2009, which does not reflect the deemed dividend expense, was $5.8 million. Included in both net loss and net loss applicable to common stock were charges associated with the Company's reductions in force made in October 2008, and January and March 2009.

R&D expenses for the first half of 2009 were $3.1 million, a decrease of $5.2 million, or 63%, compared with R&D expenses of $8.3 million in the first half of 2008. The decrease was primarily due to a $1.3 million decrease in external clinical trial expenses related to ANX-510, a $1.8 million decrease in non-clinical expenses
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
2. ADVENTRX Pharmaceuticals to Present at the 2007 Thomas Weisel Partners Healthcare Conference
3. ADVENTRX Pharmaceuticals to Present at the 20th Annual Bear Stearns Healthcare Conference
4. ADVENTRX Announces ANX-514 Clinical Development Plan Affirmed by the FDA
5. ADVENTRX Pharmaceuticals to Present at the ThinkEquity Partners Fifth Annual Growth Conference
6. ADVENTRX Pharmaceuticals to Present at the 2007 UBS Global Life Sciences Conference
7. ADVENTRX to Present ANX-514 Preclinical Data at 2007 AACR-NCI-EORTC International Conference
8. ADVENTRX Pharmaceuticals to Present at the 2007 BIOInvestor Forum
9. ADVENTRX Appoints Vice President of Commercialization
10. ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results
11. ADVENTRX Announces Consolidation of Clinical and Management Positions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... Richardson, Texas (PRWEB) October 20, 2014 ... today announced that a team from Iowa State University ... * design contest. Using a Convey HC-2ex, the team’s ... than 14 times faster than the second place finisher. ... academic world embarked upon the month long challenge, using ...
(Date:10/20/2014)... , Oct. 20, 2014 PureTech , ... tackling big healthcare problems, announced today the closing ... with participation from Invesco Perpetual, a $120 Billion ... to drive PureTech,s existing pipeline forward and to ... has the scientific creativity to really go for ...
(Date:10/19/2014)... OCTOBER 20-22, 2014: The 9th ... will take place at the Congress Center ... is now available at http://www.abim.ch . ... organizations from all over the globe will ... latest products and developments on the world ...
(Date:10/19/2014)... The report "Chocolate, Cocoa Beans, Lecithin, Sugar and ... and Forecast (2011 - 2016)," analyzes the chocolate ... the major market drivers, restraints, and opportunities for the ... The global chocolate market is expected to grow from ... an estimated CAGR of 2.7% from 2011 to 2016. ...
Breaking Biology Technology:Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 2Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 3Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 4
... ARCA biopharma, Inc.,announced today that the U.S. ... New Drug Application (NDA) for the company,s ... unique,beta-blocker and mild vasodilator developed for the ... the FDA, bucindolol could become the first,genetically ...
... HOUSTON, Sept. 22, 2008 -- Chemists at Rice University ... nanorods -- tiny, wand-like nanoparticles that are being studied ... as diagnosing disease and improving electronic viewscreens. , "The ... synthetic methods is only about 20 percent," said lead ...
... SAN DIEGO, Sept. 22 Neurocrine Biosciences,Inc. (Nasdaq: ... and Chief,Executive Officer of Neurocrine Biosciences will be presenting ... Hyatt in New York., The live presentation takes ... (ET) /7:00 a.m. Pacific Time (PT). The presentation will,be ...
Cached Biology Technology:FDA Accepts New Drug Application for Bucindolol, A Genetically-Targeted Treatment for Heart Failure From ARCA biopharma 2FDA Accepts New Drug Application for Bucindolol, A Genetically-Targeted Treatment for Heart Failure From ARCA biopharma 3Purifying nanorods: Big success with tiny cleanup 2Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference 2
(Date:10/15/2014)... virus is spreading rapidly and to an unexpected extent. ... the past and the virus shows a new disease ... before. For this reason, the German National Academy of ... and Engineering, and the Union of the German Academies ... the Ebola epidemic today. , In the statement the ...
(Date:10/15/2014)...   Neurotechnology , a provider of high-precision ... the VeriLook Surveillance 3.0 software development kit ... face identification using live video streams from single ... version not only identifies faces in a crowd, ... they are moving through the video frame. It ...
(Date:10/14/2014)... – Scientists have sequenced the house fly genome for ... might expect from an insect that thrives in pathogen-rich ... Oct. 14 in the journal Genome Biology , ... and of how flies quickly adapt to resist insecticides, ... house flies (Musca domestica) carry and transmit more than ...
Breaking Biology News(10 mins):Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 2VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 3House fly genome reveals expanded immune system 2
... Prostate cancer treatments that target the hormone androgen and its ... a new study. Researchers have found that when two genes ... for the hormone androgen, preventing prostate cells from developing normally. ... Cancer Center, suggests that the gene fusion not the ...
... HOLE, MAMitchell Sogin of the Marine Biological Laboratory (MBL) has ... Torrent of Guilford, Conn., and San Francisco. As ... sequencer, a DNA sequencing system that directly translates chemical signals ... a semiconductor chip. The result is a sequencing system that ...
... Specific dioxins derived from the antibacterial agent triclosan, used ... consumer products, account for an increasing proportion of total ... Minnesota research. The study appears online in the ... and Technology . The researchers, from the university,s ...
Cached Biology News:Gene fusions may be the 'smoking gun' in prostate cancer development, U-M study finds 2MBL scientist awarded next-generation DNA sequencer to monitor water quality 2U of Minn. study finds rising levels of dioxins from common soap ingredient in Mississippi River 2
... to the maintenance of appropriate levels ... important and diverse as those involved ... stress response, antigen presentation, modulation of ... cell cycle regulation, transcription, and signalling ...
... Receptor-gamma (PPAR) is a member of ... transcription factors that heterodimerize with retinoic ... in the regulation of glucose and ... class of anti-diabetic agents called thiazolidinediones ...
... Urine protein analysis can be used for ... to diagnose and/or monitor renal and other diseases. ... collected non-invasively in large amounts, it provides an ... source of disease biomarkers. The ProteoSpin Urine ...
... The ImageXpress 5000A automated cellular imaging and ... software system designed specifically for rapid acquisition ... throughput cell-based screening. ImageXpress is fast. ... resolution (1280 x 1024 pixels), with two ...
Biology Products: